ClinicalTrials.gg
RecruitingNCT06937203Updated Jul 8, 2026

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

A Phase 1/2 interventional study of ARO-ALK7 and Placebo in Obesity and Diabetes Mellitus, Type 2, sponsored by Arrowhead Pharmaceuticals. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Arrowhead Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Obesity with a site in New Zealand — 2 open to participants now, 7 under way, 2 of them phase 3. Obesity · New Zealand.

Planned enrollment
18th of 25
150 · median 345
Started
2025
with 1 other
Phase 1/2
2 of 26
1 open now
Registered
23rd of 26
by date
Lead sponsor
2 of 26
Arrowhead Pharmaceuticals

Among the 26 studies in Obesity with a site in New Zealand, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1/2, and was the 23rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 26 studies in Obesity with a site in New Zealand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in New Zealand have not opened yet or have stopped. Only those recruiting at a site in New Zealand →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Obesity with a site in New Zealand, or all of them as a file.
02

Study summary

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1), and the safety, tolerability, and PD of multiple doses of ARO-ALK7 in adult participants with obesity with and without T2DM, either as monotherapy or in combination with tirzepatide (Part 2).

03

Conditions studied

  • Obesity
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Obesity, defined as (BMI) between 30-50 kilograms (kg)/square meter (m\^2), inclusive, with weight at Screening not to exceed 159 kg (350 pounds [lbs])
  • At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification
  • No abnormal finding of clinical relevance at Screening that could adversely impact participant safety during the study or adversely impact study results
  • Female participants of must agree to use highly effective and male participants with female partners of childbearing potential must agree to use a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later. Participants must not donate sperm or eggs during the study for at least 90 days following the end of the study or last dose of study drug, whichever is later

Exclusion criteria

Exclusion Criteria:

  • Self-reported (or documented) weight gain or loss >5% within 3 months prior to Screening
  • Use of glucagon-like peptide-1 receptor agonist (GLP-1RAs) (liraglutide, semaglutide, etc.) for any indication within 6 months prior to Screening
  • Use of non-GLP-1R medications for weight loss within 3 months prior to Screening, including but not limited to naltrexone/bupropion, orlistat, phentermine/topiramate, and other prescription or over-the-counter medication or supplement taken for weight loss purposes
  • Obesity attributable primarily in the Investigator's opinion to medication use, monogenic or endocrinologic disorders (other than polycystic ovary syndrome)
  • History of prior surgical or device-based therapy for obesity (including endoscopic bariatric procedures)
  • Use of medications or therapies strongly associated with weight gain, alterations in body composition, or increase in muscle mass, within 3 months prior to Screening
  • Type 1 diabetes mellitus

Note: Additional inclusion/exclusion criteria may apply per protocol.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Part 1 and Part 2 (optional cohort): ARO-ALK7

    ARO-ALK7 in single (Day 1) or multiple (Days 1 and 85) ascending doses

    Drug: ARO-ALK7

  • Placebo comparator
    Part 1 and Part 2 (optional cohort): Placebo

    Placebo in single (Day 1) or multiple (Days 1 and 85) matching doses

    Drug: Placebo

  • Experimental
    Part:2: ARO-ALK7 + Tirzepatide

    ARO-ALK7 at ascending doses on Days 1 and 85 plus weekly doses of tirzepatide initiated at Day 15 through Day 253

    Drug: ARO-ALK7

  • Placebo comparator
    Part 2: Placebo + Tirzepatide

    Placebo dose on Days 1 and 85 plus weekly doses of tirzepatide initiated at Day 15 through Day 253

    Drug: Placebo

Interventions

  • DrugARO-ALK7

    Subcutaneous (SC) injection

  • DrugPlacebo

    calculated volume to match active treatment by SC injection

    Also known as: 0.9% sodium chloride

This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 253 End of Study (EOS)

Secondary outcomes

  1. Pharmacokinetics (PK) of ARO-ALK7 (Part 1 Only): Maximum Observed Plasma Concentration (Cmax)

    Time frame: Through 48 hours post-dose

  2. PK of ARO-ALK7 (Part 1 Only): Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Through 48 hours post-dose

  3. PK of ARO-ALK7 (Part 1 Only): Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24)

    Time frame: Through 48 hours post-dose

  4. PK of ARO-ALK7 (Part 1 Only): Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Quantifiable Plasma Concentration (AUC0-t)

    Time frame: Through 48 hours post-dose

  5. PK of ARO-ALK7 (Part 1 Only): Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUC0-∞)

    Time frame: Through 48 hours post-dose

  6. PK of ARO-ALK7 (Part 1 Only): Terminal Elimination Half-life (t1/2)

    Time frame: Through 48 hours post-dose

  7. PK of ARO-ALK7 (Part 1 Only): Apparent Systemic Clearance (CL/F)

    Time frame: Through 48 hours post-dose

  8. PK of ARO-ALK7 (Part 1 Only): Apparent Terminal-phase Volume of Distribution (Vz/F)

    Time frame: Through 48 hours post-dose

  9. PK of ARO-ALK7 (Part 1 Only): Recovery of Unchanged Drug in Urine from Time 0 to 24 Hours after Dosing (Amount excreted: Ae)

    Time frame: Through 24 hours post-dose

  10. PK of ARO-ALK7 (Part 1 Only): Fraction or Percentage of Administered Drug Excreted in Urine from Time 0 to 24 Hours after Dosing (Fe)

    Time frame: Through 24 hours post-dose

  11. PK of ARO-ALK7: Renal Clearance (CLr)

    Time frame: Through 24 hours post-dose

07

Study locations

7 of 8 sites recruiting
  • Research Site 8
    Morayfield, QLC 4506, Australia
    Recruiting
    • Principle Investigator · Principal investigator
  • Research Site 7
    Nedlands, Western Australia 6009, Australia
    Not yet recruiting
    • Principle Investigator · Principal investigator
  • Research Site 5
    Grafton, Auckland 1010, New Zealand
    Recruiting
    • Principle Investigator · Principal investigator
  • Research Site 6
    Papatoetoe, Auckland 2025, New Zealand
    Recruiting
    • Principle Investigator · Principal investigator
  • Research Site 3
    Takapuna, Auckland 0622, New Zealand
    Recruiting
    • Principle Investigator · Principal investigator
  • Research Site 1
    Auckland, 1010, New Zealand
    Recruiting
    • Principle Investigator · Principal investigator
  • Research Site 2
    Christchurch, 8011, New Zealand
    Recruiting
    • Principle Investigator · Principal investigator
  • Research Site 4
    Rotorua, 3010, New Zealand
    Recruiting
    • Principle Principle Investigator · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Feb 2027, 21 months after the start.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 22, 2025
StartActual
May 9, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06937203
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
May 9, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Medical Monitor
Contact
AROALK71001@arrowheadpharma.com
626-304-3400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion